Menu
  • Join
  • Login
  • Contact
 

FIP Development Goal 15: People-centred care

 

 FIP Development Goal 15 Workforce Element


FIP Development Goal 15 [w]

 

                                                                                                                                            

Globally, we will have:

Strategies in place to develop pharmaceutical education and the workforce to support the delivery of people-centred care in practice.  

Mechanisms

  • Ensure academic capacity infrastructures in place to develop people-centred-care knowledge and skills in initial education and training (FIP Development Goal 1 [w]), including in interprofessional education development (FIP Development Goal 8 [w]).

  • Embed people-centred care as a strategic outcome in earlier career training (FIP Development Goal 2 [w]) as well as throughout advanced and expert specialist development (FIP Development Goal 4 [w]).

  • Utilise people-centred care as an indicator for evaluating and developing quality assurance in education (FIP Development Goal 3 [w]), as well as for monitoring workforce impact (FIP Development Goal 11 [w]).

  • Develop competency frameworks across all stages of workforce development with people-centred care at the core (FIP Development Goal 5 [w]).

 

FIP Development Goal 15 Practice Element


FIP Development Goal 15 [p]

 

                                                                                                                                                                                                                                                

Globally, we will have:

Collaborative interprofessional strategies and people-centred professional services to support the prevention, screening, clinical management and therapeutic optimisation of non-communicable diseases (NCDs) and long-terms conditions (LTCs) including cardiovascular diseases, chronic respiratory conditions (such as asthma and chronic obstructive pulmonary disease, COPD), diabetes, cancer, mental health conditions, dermatological conditions and others.

Mechanisms

  • Develop and implement structured and evidence-based disease prevention (and secondary prevention) strategies and professional services for NCDs and LTCs, that effectively address and modify or minimise risk factors.

  • Develop and implement structured and evidence-based strategies and professional services for community-based screening and monitoring of NCDs and LTCs and their risk factors, symptoms and clinical signs through point-of-care tests and other assessment methods like structured tools and questionnaires to identify individuals that may require further diagnostics and/or care.

  • Develop and implement structured systems and protocols for the referral of potential patients to other HealthCare Professionals, and for sharing clinical findings from patient screening and monitoring across the health care team and system, namely via shared access (for consultation and input) to the patient’s (electronic) health records. 

  • Develop and implement structured and evidence-based strategies and professional services for the optimisation of treatments and medicines use, to ensure optimal clinical and quality of life outcomes and resource utilisation.

  • Develop and implement structured and evidence-based strategies and professional services for special patient populations with long-term conditions and specific needs, such as older adults, people with functional diversity, rare disease patients, poor and vulnerable patients, illiterate patients, migrant populations, refugees and other groups.

 

FIP Development Goal 15 Science Element 


FIP Development Goal 15 [s]

 

                                                                                          

Globally, we will have:

Capacity to monitor and understand health-related characteristics leading to innovative personalized approaches for improved people-centred care.

Mechanisms

  • Promote provision of science-based medicine information.

  • Collaborate with stakeholder to make available the latest relevant scientific information.

  • Support development of new medical products to meet healthcare needs.

  • Collaborate with global (the World Health Organization) and regional stakeholders to develop strategies for repurposing of licensed medicines for other conditions.


Find out more about the 21 FIP Development Goals for transforming global pharmacy here.
Last update 16 September 2020

FIP Congresses